{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:59:56Z","timestamp":1791291596040,"version":"4.3.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"vor","delay-in-days":366,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","valueinhealthjournal.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.jval.2014.10.012","type":"journal-article","created":{"date-parts":[[2015,1,28]],"date-time":"2015-01-28T10:17:12Z","timestamp":1422440232000},"page":"234-249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Critical Appraisal of Network Meta-Analyses Evaluating the Efficacy and Safety of New Oral Anticoagulants in Atrial Fibrillation Stroke Prevention Trials"],"prefix":"10.1016","volume":"18","author":[{"given":"Shannon","family":"Cope","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Clemens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Hamm\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Noack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen P.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2014.10.012_bib1","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/phar.1217","article-title":"Clinical update on the management of atrial fibrillation","volume":"33","author":"Danelich","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jval.2014.10.012_bib2","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/eurheartj\/ehi825","article-title":"Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study","volume":"27","author":"Heeringa","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jval.2014.10.012_bib3","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham Study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"key":"10.1016\/j.jval.2014.10.012_bib4","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa022913","article-title":"Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation","volume":"349","author":"Hylek","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2014.10.012_bib5","unstructured":"National Collaborating Centre for Chronic Conditions. Atrial Fibrillation: National Clinical Guideline for Management in Primary and Secondary Care. London: Royal College of Physicians, 2006. Available from: http:\/\/www.nice.org.uk\/nicemedia\/live\/10982\/30055\/30055.pdf. [Accessed September 22, 2013]."},{"key":"10.1016\/j.jval.2014.10.012_bib6","first-page":"327","article-title":"Strategies for primary and secondary stroke prevention in atrial fibrillation","volume":"66","author":"Finsterer","year":"2008","journal-title":"Neth J Med"},{"key":"10.1016\/j.jval.2014.10.012_bib7","doi-asserted-by":"crossref","first-page":"688","DOI":"10.7326\/0003-4819-131-9-199911020-00010","article-title":"Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention","volume":"131","author":"Hart","year":"1999","journal-title":"Am Intern Med"},{"issue":"Suppl","key":"10.1016\/j.jval.2014.10.012_bib8","doi-asserted-by":"crossref","first-page":"194S","DOI":"10.1378\/chest.119.1_suppl.194S","article-title":"Antithrombotic therapy in atrial fibrillation","volume":"119","author":"Albers","year":"2001","journal-title":"Chest"},{"issue":"1, Suppl.","key":"10.1016\/j.jval.2014.10.012_bib9","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1378\/chest.119.1_suppl.64S","article-title":"Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety","volume":"119","author":"Hirsh","year":"2001","journal-title":"Chest"},{"issue":"3, Suppl.","key":"10.1016\/j.jval.2014.10.012_bib10","first-page":"S72","article-title":"Novel antithrombotic therapies for the prevention of stroke in patients with atrial fibrillation","volume":"10","author":"O\u2019Donnell","year":"2004","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jval.2014.10.012_bib11","first-page":"173","article-title":"Adherence to a new oral anticoagulant treatment prescription: dabigatran etexilate","volume":"3","author":"Bellamy","year":"2009","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jval.2014.10.012_bib12","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.amjmed.2009.11.015","article-title":"Are atrial fibrillation patients receiving warfarin in accordance with stroke risk?","volume":"123","author":"Zimetbaum","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.jval.2014.10.012_bib13","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.amjmed.2009.11.025","article-title":"Underuse of oral anticoagulants in atrial fibrillation: a systematic review","volume":"123","author":"Ogilvie","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.jval.2014.10.012_bib14","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2014.10.012_bib15","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMc1007378","article-title":"Newly identified events in the RE-LY trial","volume":"363","author":"Connolly","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2014.10.012_bib16","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2014.10.012_bib17","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2014.10.012_bib18","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1002\/sim.1566","article-title":"A chain of evidence with mixed comparisons: models for multi-parameter synthesis and consistency of evidence","volume":"22","author":"Ades","year":"2003","journal-title":"Stat Med"},{"key":"10.1016\/j.jval.2014.10.012_bib19","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons","volume":"23","author":"Lu","year":"2004","journal-title":"Stat Med"},{"key":"10.1016\/j.jval.2014.10.012_bib20","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/j.1524-4733.2008.00347.x","article-title":"Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons","volume":"11","author":"Jansen","year":"2008","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2014.10.012_bib21","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jval.2011.04.002","article-title":"Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1","volume":"14","author":"Jansen","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2014.10.012_bib22","unstructured":"Wells GA, Sultan SA, Chen L, et al. Indirect evidence: indirect treatment comparisons in meta-analysis. 2009. Available from: http:\/\/webcache.googleusercontent.com\/search?q=cache:LvF0Ql-sLBAJ:www.cadth.ca\/en\/products\/methods-and-guidelines\/publication\/884+&cd=1&hl=en&ct=clnk&gl=ca. [Accessed September 22, 2013]."},{"key":"10.1016\/j.jval.2014.10.012_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta9260","article-title":"Indirect comparisons of competing interventions","volume":"9","author":"Glenny","year":"2005","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.jval.2014.10.012_bib24","unstructured":"Sch\u00f6ttker B, Luhmann D, Boulkheimair D, Raspe H. Indirekte vergleiche von therapieverfahren. 2009. Available from: portal.dimdi.de\/de\/hta\/hta_berichte\/hta243_bericht_de.pdf. [Accessed September 22, 2013]."},{"key":"10.1016\/j.jval.2014.10.012_bib25","unstructured":"Cucherat M, Izard V. Les comparaisons indirectes M\u00e9thodes et validit\u00e9. 2009. Available from: http:\/\/www.has-sante.fr\/portail\/jcms\/c_998796\/fr\/les-comparaisons-indirectes-methodes-et-validite. [Accessed September 22, 2013]."},{"key":"10.1016\/j.jval.2014.10.012_bib26","doi-asserted-by":"crossref","first-page":"f3675","DOI":"10.1136\/bmj.f3675","article-title":"Analysis of the systematic reviews process in reports of network meta-analyses: methodological systematic review","volume":"347","author":"Bafeta","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.jval.2014.10.012_bib27","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1177\/0272989X13485156","article-title":"Evidence synthesis for decision making: a reviewer\u2019s checklist","volume":"33","author":"Ades","year":"2013","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2014.10.012_bib28","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jval.2014.01.004","article-title":"Indirect treatment comparison\/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report","volume":"17","author":"Jansen","year":"2014","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2014.10.012_bib29","unstructured":"Adam SS, McDuffie JR, Ortel TL, Williams JW. Comparative effectiveness of warfarin and newer oral anticoagulants for the long-term prevention and treatment of arterial and venous thromboembolism (VA-ESP Project #09-010). 2012. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK97541\/. [Accessed September 22, 2013]."},{"key":"10.1016\/j.jval.2014.10.012_bib30","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1160\/TH11-11-0784","article-title":"clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a \u2018real world\u2019 atrial fibrillation population: a modelling analysis based on a nationwide cohort study","volume":"107","author":"Banerjee","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jval.2014.10.012_bib31","doi-asserted-by":"crossref","unstructured":"Wells G, Coyle D, Cameron C, et al. Safety, effectiveness, and cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with arterial fibrillation. 2012. Available from: http:\/\/cadth.ca\/media\/pdf\/NOAC_Therapeutic_Review_final_report.pdf. [Accessed September 22, 2013].","DOI":"10.1016\/j.jval.2013.01.009"},{"key":"10.1016\/j.jval.2014.10.012_bib32","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.ijcard.2012.03.148","article-title":"Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: a meta-analysis of 50,578 patients","volume":"167","author":"Capodanno","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jval.2014.10.012_bib33","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1161\/CIRCULATIONAHA.112.115410","article-title":"Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature","volume":"126","author":"Dentali","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jval.2014.10.012_bib34","unstructured":"Edwards A, Hamilton V, Nherera L, et al. Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (HTA Programme Project #10\/75 2011). 2011. Available from: www.nice.org.uk\/nicemedia\/live\/13746\/59295\/59295.pdf. [Accessed September 22, 2013]."},{"key":"10.1016\/j.jval.2014.10.012_bib35","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1161\/STROKEAHA.112.673558","article-title":"Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials","volume":"43","author":"Ntaios","year":"2012","journal-title":"Stroke"},{"key":"10.1016\/j.jval.2014.10.012_bib36","doi-asserted-by":"crossref","first-page":"e7097","DOI":"10.1136\/bmj.e7097","article-title":"Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis","volume":"345","author":"Rasmussen","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.jval.2014.10.012_bib37","unstructured":"Spackman E, Burch J, Faria R, et al. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a single technology appraisal. 2011. Available from: www.nice.org.uk\/nicemedia\/live\/12225\/55919\/55919.pdf. [Accessed September 21, 2013]."},{"key":"10.1016\/j.jval.2014.10.012_bib38","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/archinternmed.2011.1666","article-title":"Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials","volume":"172","author":"Uchino","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jval.2014.10.012_bib39","unstructured":"Coleman CI, Phung OJ, Cappelleri JC, et al. Use of Mixed Treatment Comparisons in Systematic Reviews: Methods Research Report (Prepared by the University of Connecticut\/Hartford Hospital Evidence-based Practice Center under Contract No. 290-2007-10067-I; AHRQ Publication No. 12-EHC119-EF). Rockville, MD: Agency for Healthcare Research and Quality, 2012. Available from: http:\/\/www.effectivehealthcare.ahrq.gov\/search-for-guides-reviews-and-reports\/?pageaction=displayproduct&productID=1238. [Accessed September 22, 2013]."},{"key":"10.1016\/j.jval.2014.10.012_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjopen-2012-001592","article-title":"Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials","volume":"2","author":"Mak","year":"2012","journal-title":"BMJ Open"},{"key":"10.1016\/j.jval.2014.10.012_bib41","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.amjcard.2012.03.049","article-title":"Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation","volume":"110","author":"Miller","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jval.2014.10.012_bib42","doi-asserted-by":"crossref","first-page":"62","DOI":"10.5482\/HAMO-12-11-0021","article-title":"Clinical trials with new oral anticoagulants: additive value of indirect comparisons also named network meta-analyses","volume":"33","author":"Harenberg","year":"2013","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.jval.2014.10.012_bib43","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1161\/CIRCOUTCOMES.112.966572","article-title":"Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation","volume":"5","author":"Baker","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jval.2014.10.012_bib44","first-page":"330","article-title":"Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis","volume":"31","author":"Harenberg","year":"2012","journal-title":"Int Angiol"},{"key":"10.1016\/j.jval.2014.10.012_bib45","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1160\/TH12-06-0388","article-title":"Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada: comparative efficacy and cost-effectiveness","volume":"108","author":"Kansal","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jval.2014.10.012_bib46","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jacc.2012.03.019","article-title":"Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation","volume":"60","author":"Lip","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jval.2014.10.012_bib47","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1160\/TH12-02-0093","article-title":"An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation","volume":"108","author":"Mantha","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jval.2014.10.012_bib48","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1160\/TH10-10-0642","article-title":"Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate","volume":"104","author":"Roskell","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jval.2014.10.012_bib49","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1161\/CIRCOUTCOMES.112.965988","article-title":"Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation","volume":"5","author":"Schneeweiss","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jval.2014.10.012_bib50","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/qjmed\/hcs114","article-title":"Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation","volume":"105","author":"Testa","year":"2012","journal-title":"QJM"},{"key":"10.1016\/j.jval.2014.10.012_bib51","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.amjcard.2007.06.034","article-title":"Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study)","volume":"100","author":"Ezekowitz","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jval.2014.10.012_bib52","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1253\/circj.CJ-10-1183","article-title":"Safety and efficacy of the oral direct factor xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation\u2014The ARISTOTLE-J study","volume":"75","author":"Ogawa","year":"2011","journal-title":"Circ J"},{"key":"10.1016\/j.jval.2014.10.012_bib53","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1253\/circj.CJ-12-0454","article-title":"Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation","volume":"76","author":"Hori","year":"2012","journal-title":"Circ J"},{"key":"10.1016\/j.jval.2014.10.012_bib54","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2014.10.012_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.jval.2014.10.012_bib56","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jval.2014.10.012_bib57","unstructured":"NHS Quality Improvement Scotland. SIGN 50: a guideline developer\u2019s handbook. Available from: www.sign.ac.uk\/pdf\/sign50.pdf. [Accessed September 22, 2013]."},{"key":"10.1016\/j.jval.2014.10.012_bib58","unstructured":"Agency for Healthcare Research and Quality. Methods Guide for Effectiveness and Comparative Effectiveness Reviews (AHRQ publication no. 10(11)-EHC063-EF). Rockville, MD: Agency for Healthcare Research and Quality, 2011. Available from: http:\/\/effectivehealthcare.ahrq.gov\/index.cfm\/search-for-guides-reviews-and-reports\/?pageaction=displayproduct&productid=318. [Accessed September 22, 2013]."},{"key":"10.1016\/j.jval.2014.10.012_bib59","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.jclinepi.2012.01.002","article-title":"Direct acyclic graphs can help understand bias in indirect and mixed treatment comparisons","volume":"65","author":"Jansen","year":"2012","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jval.2014.10.012_bib60","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/sim.1187","article-title":"How should meta-regression analyses be undertaken and interpreted?","volume":"21","author":"Thompson","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.jval.2014.10.012_bib61","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1538-7836.2007.02848.x","article-title":"Double-blind studies are not always optimum for evaluation of a novel therapy: the case of new anticoagulants","volume":"6","author":"Buller","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jval.2014.10.012_bib62","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1111\/j.1538-7836.2011.04507.x","article-title":"External and internal validity of open label or double-blind trials in oral anticoagulation: better, worse or just different?","volume":"9","author":"Beyer-Westendorf","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jval.2014.10.012_bib63","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/jrsm.25","article-title":"Network meta-analysis of parametric survival curves","volume":"1","author":"Ouwens MJNM","year":"2010","journal-title":"Res Synt Methods"},{"key":"10.1016\/j.jval.2014.10.012_bib64","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1471-2288-11-61","article-title":"Network meta-analysis of survival data with fractional polynomials","volume":"11","author":"Jansen","year":"2011","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jval.2014.10.012_bib65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2288-12-152","article-title":"Meta-regression models to address heterogeneity and inconsistency in network meta-analysis of survival outcomes","volume":"12","author":"Jansen","year":"2012","journal-title":"BMC Med Res Meth"},{"key":"10.1016\/j.jval.2014.10.012_bib66","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1177\/1076029613486539","article-title":"The efficacy and safety of oral anticoagulants in warfarin-suitable patients with nonvalvular atrial fibrillation: systematice review and meta-analysis","volume":"19","author":"Mitchell","year":"2013","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.jval.2014.10.012_bib67","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.clinthera.2013.05.011","article-title":"Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation","volume":"35","author":"Assiri","year":"2013","journal-title":"Clin Ther"},{"key":"10.1016\/j.jval.2014.10.012_bib68","doi-asserted-by":"crossref","unstructured":"Bruins Slot KMH, Berge E, Saxena R, et al. Oral anticoagulants versus antiplatelet therapy for preventing stroke and systemic embolic events in patients with atrial fibrillation (Protocol). Cochrane Database Syst Rev 2012;Issue 2: Art. No. CD009538. 10.1002\/14651858.CD009538","DOI":"10.1002\/14651858.CD009538"},{"key":"10.1016\/j.jval.2014.10.012_bib69","doi-asserted-by":"crossref","unstructured":"Mahtani KR, Heneghan CJ, Tai TW. Direct thrombin inhibitors and factor Xa inhibitors for atrial fibrillation (Protocol). Cochrane Database Syst Rev 2012;Issue 4: Art. No. CD009787. 10.1002\/14651858.CD009787.","DOI":"10.1002\/14651858.CD009787"},{"key":"10.1016\/j.jval.2014.10.012_bib70","unstructured":"Gauthier K., Bai B., Moulton K., et al. Antithrombotic agents for the prevention of stroke and other thrombotic events in patients with atrial fibrillation. Available from: http:\/\/www.crd.york.ac.uk\/PROSPERO\/display_record.asp?ID=CRD42012002721. [Accessed September 22, 2013]."},{"key":"10.1016\/j.jval.2014.10.012_bib71","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1002\/sim.3594","article-title":"Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation","volume":"28","author":"Cooper","year":"2009","journal-title":"Stat Med"},{"key":"10.1016\/j.jval.2014.10.012_bib72","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1160\/TH12-07-0463","article-title":"Head-to-head or indirect comparisons of the novel oral anticoagulants in atrial fibrillation: what\u2019s next?","volume":"108","author":"Harenberg","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jval.2014.10.012_bib73","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1002\/sim.5539","article-title":"Extending methods for investigating the relationship between treatment effect and baseline risk from pairwise meta-analysis to network meta-analysis","volume":"32","author":"Achana","year":"2013","journal-title":"Stat Med"},{"key":"10.1016\/j.jval.2014.10.012_bib74","unstructured":"Higgins JPT, Green SE, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from: http:\/\/www.cochrane-handbook.org. [Accessed September 22, 2013]"},{"key":"10.1016\/j.jval.2014.10.012_bib75","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1002\/(SICI)1097-0258(19971215)16:23<2741::AID-SIM703>3.0.CO;2-0","article-title":"Investigating underlying risk as a source of heterogeneity in meta-analysis","volume":"16","author":"Thompson","year":"1997","journal-title":"Stat Med"},{"key":"10.1016\/j.jval.2014.10.012_bib76","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1002\/sim.4194","article-title":"A stochasitic multicriteria model for evidence-based decision making in drug benefit risk-analysis","volume":"30","author":"Tervonen","year":"2011","journal-title":"Stat Med"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109830151404738X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109830151404738X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T16:50:43Z","timestamp":1651078243000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109830151404738X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":76,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S109830151404738X"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2014.10.012","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Critical Appraisal of Network Meta-Analyses Evaluating the Efficacy and Safety of New Oral Anticoagulants in Atrial Fibrillation Stroke Prevention Trials","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2014.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}